CC BY-NC-ND 4.0 · J Lab Physicians 2023; 15(01): 056-061
DOI: 10.1055/s-0042-1750078
Original Article

SARS-CoV-2: The Self-Nonself Issue and Diagnostic Tests

1   Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, Bari, Italy
› Author Affiliations
Funding None.
 

Abstract

Objective At present, false negatives/positives have been reported in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics. Searching for the molecular basis of such tests' unreliability, this study aimed at defining how specific are the sequences used in serological and polymerase chain reaction (PCR) tests to detect SARS-CoV-2.

Materials and Methods Analyses were performed on the leading SARS-CoV-2 biomarker spike glycoprotein (gp). Sharing of peptide sequences between the spike antigen and the human host was analyzed using the Peptide Search program from Uniprot database. Sharing of oligonucleotide sequences was investigated using the nucleotide Basic Local Alignment Search Tool (BLASTn) from National Center for Biotechnology Information (NCBI).

Results Two main points stand out: (1) a massive pentapeptide sharing exists between the spike gp and the human proteome, and only a limited number of pentapeptides (namely 107) identify SARS-CoV-2 spike gp as nonself when compared with the human proteome, and (2) the small phenetic difference practically disappears at the genetic level. Indeed, almost all of the 107 pentadecameric nucleotide sequences coding for the pentapeptides unique to SARS-CoV-2 spike gp are present in human nucleic acids too.

Conclusion The data are of immunological significance for defining the issue of the viral versus human specificity and likely explain the fact that false positives can occur in serological and PCR tests for SARS-CoV-2 detection.


#

Introduction

Canonical immunology lays on the concept that the human immune system evolved to attack and destroy extraneous entities such as infectious pathogens (that is, the “nonself”), in this way defending the human host (that is, the “self”) from harmful infections.[1] Accordingly, self-reactive lymphocytes that might react with peptides/structures present in the human host are selectively deleted from the immune repertoire to protect the host from self-reactivity.[1] [2]

Hence, identification and mathematical definition of self and nonself entities are a conditio sine qua non for furthering our still incomplete understanding of the immune system,[3] exploiting the immunogenic potential of vaccines in fighting infectious agents, and formulating specific diagnostic tools.[4] Indeed, discriminating self from nonself currently is all the more necessary at the molecular level because in silico comparative sequence analyses[5] [6] have documented that a high level of peptide sharing exists between pathogens and the human host. Immunologically, this peptide sharing highlights the risk that serological immunoassays for measuring patients' immune responses against a pathogen might actually reflect the extent of cross-reactivity phenomena targeting human proteins.[7]

In this scientific framework, taking the clue from recent data on the peptide sharing between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Homo sapiens,[8] [9] [10] [11] [12] the present study used SARS-CoV-2 spike glycoprotein (gp) as a research model and mathematically quantified the phenetic and genetic sequence differences that characterize the viral antigen as nonself when compared with the human host. That is, the entire human proteome was searched for peptide sequences shared with the viral gp. Pentapeptides were used as scanning probes to determine the exact viral versus human peptide sharing because a five amino acid grouping is the minimal antigenic and immunogenic space sufficient to specify an immune reaction, that is five amino acids represent the immune measurement unit.[13] [14] [15] [16] [17] [18] [19] [20] Specifically, the research was addressed to find pentapeptide identities, i.e., perfect matches, between SARS-CoV-2 gp and human proteins. This is because for a perfect peptide match (i.e., 5/5 identities and no gaps allowed) there is one and only one corresponding nucleotide sequence while for a homologous peptide (i.e., a peptide where four out of five amino acids are identical but there is a gap) there would be more corresponding nucleotide sequences depending on the gap position.[20]

Following whole human proteome analyses, data were obtained showing that only a handful of pentapeptides (exactly 107 out of 1,269 pentapeptides) are uniquely present in the viral protein antigen and absent in the human host, in this way specifying the SARS-CoV-2 spike gp as nonself when compared with the human proteome. However, this phenetic difference disappears at the genetic level. Indeed, furthering at the nucleotide level the sequence analyses revealed that the pentadecameric oligonucleotides coding for the 107 pentapeptides present in the SARS-CoV-2 spike gp and not expressed in the human proteome actually are present in human nucleic acids too.


#

Materials and Methods

SARS-CoV-2 spike amino acid and nucleotide sequences were retrieved from isolate Wuhan-Hu-1, GenBank: MN908947.3. The viral protein antigen, which is 1,273 amino acids long, was dissected into 1,269 pentapeptides offset by 1 residue, that is, overlapped each other by 4 residues (i.e., MFVFL, FVFLV, VFLVL, and so forth). Next, for each viral pentapeptide, the entire human proteome was searched for occurrences of the same pentapeptide match by using PIR Peptide match (https://research.bioinformatics.udel.edu/peptidematch/index.jsp) and Peptide Search program (https://www.uniprot.org/peptidesearch/).[21]

Viral pentapeptides that are absent in the human proteome were further investigated at the genetic level using the nucleotide Basic Local Alignment Search Tool (BLASTn) program (http://blast.ncbi.nlm.nih.gov).[22] [23] That is, for each pentapeptide unique to SARS-CoV-2 spike gp, the corresponding coding pentadecameric oligonucleotide sequence was used as a probe to scan the entire human NCBI (National Center for Biotechnology Information) nucleotide collection searching for instances of the same identical oligonucleotide sequence (i.e., 15/15 identities and no gaps allowed).


#

Results

SARS-CoV-2 Spike gp versus the Human Proteome: Self-Nonself at the Phenetic Level

Following PIR matching analyses of the SARS-CoV-2 spike gp versus the entire human proteome, the SARS-CoV-2 spike gp self could be defined as a set of 107 pentapeptide perfect matches. That is, only 107 out of 1,269 viral pentapeptides uniquely occur in the SARS-CoV-2 antigen and represent the molecular signature of the viral antigen, while the remaining 1,162 viral pentapeptides occur in the human proteome. [Table 1] describes the pentapeptides unique to SARS-CoV-2 spike gp.

Table 1

SARS-CoV-2 spike gp pentapeptides that are absent in the human proteome

Pos[a]

Sequence[b]

Pos[a]

Sequence[b]

Pos[a]

Sequence[b]

Pos[a]

Sequence[b]

34

RGVYY

230

PIGIN

538

CVNFN

901

MAYRF

35

GVYYP

257

GWTAG

617

CTEVP

904

RFNGI

36

VYYPD

264

AYYVG

651

IGAEH

1028

MSECV

37

YYPDK

280

NENGT

674

YQTQT

1045

GYHLM

61

NVTWF

297

SETKC

675

QTQTN

1046

YHLMS

62

VTWFH

311

GIYQT

693

IAYTM

1072

KNFTT

63

TWFHA

350

VYAWN

694

AYTMS

1078

PAICH

65

FHAIH

351

YAWNR

734

TSVDC

1097

NGTHW

85

PFNDG

361

CVADY

737

DCTMY

1098

GTHWF

101

IRGWI

375

STFKC

739

TMYIC

1099

THWFV

102

RGWIF

377

FKCYG

740

MYICG

1100

HWFVT

105

IFGTT

378

KCYGV

745

DSTEC

1101

WFVTQ

130

VCEFQ

379

CYGVS

759

FCTQL

1104

TQRNF

131

CEFQF

393

TNVYA

793

PIKDF

1107

NFYEP

132

EFQFC

418

IADYN

836

QYGDC

1129

IGIVN

136

CNDPF

420

DYNYK

837

YGDCL

1134

NTVYD

143

VYYHK

421

YNYKL

838

GDCLG

1209

IKWPW

148

NNKSW

433

VIAWN

848

DLICA

1210

KWPWY

149

NKSWM

435

AWNSN

849

LICAQ

1211

WPWYI

152

WMESE

436

WNSNN

850

ICAQK

1214

YIWLG

153

MESEF

477

STPCN

851

CAQKF

1215

IWLGF

160

YSSAN

479

PCNGV

868

MIAQY

1224

IAIVM

166

CTFEY

485

GFNCY

883

SGWTF

1233

LCCMT

184

GNFKN

486

FNCYF

885

WTFGA

1234

CCMTS

199

GYFKI

493

QSYGF

897

FAMQM

1236

MTSCC

203

IYSKH

534

VKNKC

899

MQMAY

1253

CCKFD

204

YSKHT

536

NKCVN

900

QMAYR

a Position along the SARS-CoV-2 spike gp.


b Amino acid sequence in one-letter code.


Hence, a first datum provided from this study is that serological tests to measure the extent of the antiviral immune response might equate mostly to measuring the immune response against proteins of the human host.


#

SARS-CoV-2 Spike Gene versus the Human Genome: Self-Nonself at the Genetic Level

As a second step, the 107 pentapeptides that are absent in the human proteome and uniquely present in the spike gp were controlled at the genetic level for oligonucleotide sharing. The scientific rationale at the basis of such control analyses is the following. If the absence of the 107 pentapeptides described in [Table 1] marks and differentiates the viral gp antigen from the human proteome, as a logical consequence such an absence must exist at the nucleic acid level too, by being nucleic acids the ultimate repository of the information that specifies and identifies proteins and organisms.

On that account, human nucleic acids were searched for oligonucleotide sequences coding for the SARS-CoV-2 spike gp pentapeptides not expressed in the human proteome. The results obtained by using the BLASTn program are illustrated in [Table 2] that shows that practically all pentadecameric oligonucleotide sequences corresponding to the unique 107 SARS-CoV-2 spike gp pentapeptides occur and often repeatedly recur in coding and/or noncoding human nucleic acids. Exception is the pentapeptide YSSAN (amino acid position: 160–164), the corresponding oligonucleotide of which was repeatedly found at the 13mer level.

Table 2

Occurrences in human nucleic acids of the pentadecameric oligonucleotides coding the 107 pentapeptides uniquely present in SARS-CoV-2 spike gp

Pentapeptide[a]

5′-Oligodeoxynucleotide-3′[b] [c]

Occurrences in human nucleic acids

Plus strand

Minus strand

RGVYY

CGTGGTGTTTATTAC

1

1

GVYYP

GGTGTTTATTACCCT

4

VYYPD

GTTTATTACCCTGAC

2

YYPDK

TATTACCCTGACAAA

13

4

NVTWF

AATGTTACTTGGTTC

7

7

VTWFH

GTTACTTGGTTCCAT

5

11

TWFHA

ACTTGGTTCCATGCT

12

14

FHAIH

TTCCATGCTATACAT

13

9

PFNDG

CCATTTAATGATGGT

8

12

IRGWI

ATAAGAGGCTGGATT

3

7

RGWIF

AGAGGCTGGATTTTT

41

59

IFGTT

ATTTTTGGTACTACT

13

11

VCEFQ

GTCTGTGAATTTCAA

15

21

CEFQF

TGTGAATTTCAATTT

46

64

EFQFC

GAATTTCAATTTTGT

46

43

CNDPF

TGTAATGATCCATTT

20

21

VYYHK

GTTTATTACCACAAA

17

19

NNKSW

AACAACAAAAGTTGG

18

19

NKSWM

AACAAAAGTTGGATG

22

31

WMESE

TGGATGGAAAGTGAG

29

25

MESEF

ATGGAAAGTGAGTTC

6

19

YSSAN

TATTCTAGTGCGAAT

CTFEY

TGCACTTTTGAATAT

2

7

GNFKN

GGTAATTTCAAAAAT

30

45

GYFKI

GGTTATTTTAAAATA

54

71

IYSKH

ATATATTCTAAGCAC

18

30

YSKHT

TATTCTAAGCACACG

5

2

PIGIN

CCAATAGGTATTAAC

4

20

GWTAG

GGTTGGACAGCTGGT

5

11

AYYVG

GCTTATTATGTGGGT

18

21

NENGT

AATGAAAATGGAACC

28

10

SETKC

TCAGAAACAAAGTGT

21

27

GIYQT

GGAATCTATCAAACT

3

10

VYAWN

GTTTATGCTTGGAAC

2

2

YAWNR

TATGCTTGGAACAGG

5

8

CVADY

TGTGTTGCTGATTAT

10

15

STFKC

TCCACTTTTAAGTGT

19

17

FKCYG

TTTAAGTGTTATGGA

13

15

KCYGV

AAGTGTTATGGAGTG

2

1

CYGVS

TGTTATGGAGTGTCT

2

TNVYA

ACTAATGTCTATGCA

5

6

IADYN

ATTGCTGATTATAAT

44

43

DYNYK

GATTATAATTATAAA

63

46

YNYKL

TATAATTATAAATTA

71

82

VIAWN

GTTATAGCTTGGAAT

6

13

AWNSN

GCTTGGAATTCTAAC

17

4

WNSNN

TGGAATTCTAACAAT

15

23

STPCN

AGCACACCTTGTAAT

7

6

PCNGV

CCTTGTAATGGTGTT

9

4

GFNCY

GGTTTTAATTGTTAC

10

13

FNCYF

TTTAATTGTTACTTT

50

29

QSYGF

CAATCATATGGTTTC

10

27

VKNKC

GTTAAAAACAAATGT

35

56

NKCVN

AAAAACAAATGTGTC

19

44

CVNFN

TGTGTCAATTTCAAC

60

42

CTEVP

TGCACAGAAGTCCCT

21

9

IGAEH

ATAGGGGCTGAACAT

1

3

YQTQT

TATCAGACTCAGACT

37

21

QTQTN

CAGACTCAGACTAAT

9

7

IAYTM

ATTGCCTACACTATG

1

4

AYTMS

GCCTACACTATGTCA

1

1

TSVDC

ACATCAGTAGATTGT

12

8

DCTMY

GATTGTACAATGTAC

1

TMYIC

ACAATGTACATTTGT

18

32

MYICG

ATGTACATTTGTGGT

13

21

DSTEC

GATTCAACTGAATGC

1

2

FCTQL

TTTTGTACACAATTA

9

12

PIKDF

CCAATTAAAGATTTT

26

22

QYGDC

CAATATGGTGATTGC

1

YGDCL

TATGGTGATTGCCTT

3

GDCLG

GGTGATTGCCTTGGT

3

5

DLICA

GACCTCATTTGTGCA

5

2

LICAQ

CTCATTTGTGCACAA

6

12

ICAQK

ATTTGTGCACAAAAG

19

37

CAQKF

TGTGCACAAAAGTTT

23

19

MIAQY

ATGATTGCTCAATAC

1

5

SGWTF

TCTGGTTGGACCTTT

53

42

WTFGA

TGGACCTTTGGTGCA

1

FAMQM

TTTGCTATGCAAATG

26

15

MQMAY

ATGCAAATGGCTTAT

5

9

QMAYR

CAAATGGCTTATAGG

4

1

MAYRF

ATGGCTTATAGGTTT

9

10

RFNGI

AGGTTTAATGGTATT

1

5

MSECV

ATGTCAGAGTGTGTA

6

6

GYHLM

GGCTATCATCTTATG

1

YHLMS

TATCATCTTATGTCC

4

KNFTT

AAGAACTTCACAACT

5

8

PAICH

CCTGCCATTTGTCAT

17

13

NGTHW

AATGGCACACACTGG

14

11

GTHWF

GGCACACACTGGTTT

4

11

THWFV

ACACACTGGTTTGTA

5

4

HWFVT

CACTGGTTTGTAACA

5

5

WFVTQ

TGGTTTGTAACACAA

52

54

TQRNF

ACACAAAGGAATTTT

47

62

NFYEP

AATTTTTATGAACCA

22

35

IGIVN

ATAGGAATTGTCAAC

3

1

NTVYD

AACACAGTTTATGAT

15

15

IKWPW

ATAAAATGGCCATGG

27

25

KWPWY

AAATGGCCATGGTAC

5

3

WPWYI

TGGCCATGGTACATT

12

5

YIWLG

TACATTTGGCTAGGT

2

4

IWLGF

ATTTGGCTAGGTTTT

18

14

IAIVM

ATTGCCATAGTAATG

9

5

LCCMT

CTTTGCTGTATGACC

4

14

CCMTS

TGCTGTATGACCAGT

2

6

MTSCC

ATGACCAGTTGCTGT

11

2

CCKFD

TGCTGCAAATTTGAT

11

21

a Pentapeptides uniquely present in SARS-CoV-2 spike gp when compared with the human proteome.


b Oligodeoxynucleotide sequences coding for pentapeptides unique to SARS-CoV-2 spike gp.


c Each pentadecameric oligodeoxynucleotide sequence was used as a probe to scan the entire human NCBI nucleotide collection for exact 15/15 identities with no gaps allowed, using BLASTn program.[22] [23] Further data and details are available at http://blast.ncbi.nlm.nih.gov.



#
#

Discussion

This study analyzes the pentapeptide sharing between SARS-CoV-2 spike gp and the human proteome, and mathematically defines the identity of the viral antigen as a set of 107 pentapeptides uniquely present in the spike gp and absent in the human proteins. Crucially, this viral versus human phenetic specificity disappears at the genetic level. The data have relevant implications in SARS-CoV-2 immunology, vaccinology, and clinical diagnostics.

Indeed, in the immunological context described under Introduction, the presence in human nucleic acids of the oligonucleotide sequences coding for the 107 pentapeptides that phenetically specify the viral antigen fails to support the deterministic hypothesis according to which the immune system evolved to discriminate infectious nonself from noninfectious self.[1] [2] [3] Rather, [Tables 1] and [2] suggest that SARS-CoV-2 and humans derived their genetic information from common ancestral templates. In this regard, this study supports the viral eukaryogenesis hypothesis, according to which the primordial eukaryotic cell was a consortium consisting of a viral ancestor of the nucleus, an archaeal ancestor of the eukaryotic cytoplasm, and a bacterial ancestor of mitochondria.[24] [25] [26]

Moreover, the present data confirm and strengthen the concept[27] [28] [29] [30] [31] [32] that only vaccine formulations based on peptide sequences uniquely present in infectious pathogens and absent in the host proteins have the potential to selectively hit the pathogens and halt infections. In the case in point, by being absent in the human proteome, the unique SARS-CoV-2 spike gp peptides described in [Table 1] represent an ideal basic peptidome platform that could result in effective and highly specific anti-SARS-CoV-2 vaccines exempt from harmful cross-reactivity.

Clinically and of utmost importance in diagnostics, the viral versus human pentapeptide and oligonucleotide sharing shown in [Table 1] and [2], respectively, could have a severe impact on the validity of the current polymerase chain reaction (PCR) tests for SARS-CoV-2 spike detection. In fact, claims have been reported about the rates of false negatives/positives in SARS-CoV-2 detection by means of serological and PCR tests,[33] [34] [35] [36] [37] [38] in this way raising numerous concerns. As observed by Viswanathan et al,[39] healthy individuals may be falsely identified as positive, requiring confirmatory testing and potentially leading to the unnecessary isolation of these individuals. In agreement, Gubbay et al[40] suggested that large-scale SARS-CoV-2 screening testing initiatives among low pretest probability populations should be evaluated thoroughly prior to implementation given the risk of false positives and consequent potential for harm at the individual and population levels, and this not to mention the enormous waste of economic resources that might be caused by unreliable large-scale SARS-CoV-2 tests. As a matter of fact, data from [Table 1] clearly suggest that serological immunoassays for measuring antipathogen antibody response might actually be indicative of cross-reactions with human proteins. In line with [Table 1], [Table 2] indicates that SARS-CoV-2 spike detection by PCR might be affected by the risk that human nucleotide sequences can be amplified, thus generating false-positive results with consequent wrong medical diagnoses. Such a risk is real in light of the fact that oligonucleotide sequences have been shown to be shared between the human genome and primers that have been proposed/used for SARS-CoV-2 detection by PCR.[41] Therefore, this study might be of help not only to understand cross-reactivity phenomena and to address new specific peptide-based approaches in anti-SARS-CoV-2 vaccinal protocols but also to define a specific and precise diagnostics of SARS-CoV-2 infection and disease.

In closing, it is also worth noting that, in agreement with reports from this laboratory,[8] [10] [11] [42] [43] [44] Khavinson et al[45] have recently described an intense peptide sharing between almost all the SARS-CoV-2 proteins and human proteins, with hepta- and octamers scattered along the entire length of the SARS-CoV-2 spike protein molecule, thus furtherly supporting the possibility of cross-reactivity and consequent autoimmunity between SARS-CoV-2 and the human host.[7]


#
#

Conflicts of Interest

None declared.

  • References

  • 1 Janeway Jr CA. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992; 13 (01) 11-16
  • 2 Rose NR. Negative selection, epitope mimicry and autoimmunity. Curr Opin Immunol 2017; 49: 51-55
  • 3 Kanduc D. Immunobiology: on the inexistence of a negative selection process. Adv Stud Biol 2020; 12 (01) 19-28
  • 4 Pradeu T, Carosella ED. On the definition of a criterion of immunogenicity. Proc Natl Acad Sci U S A 2006; 103 (47) 17858-17861
  • 5 Kanduc D, Stufano A, Lucchese G, Kusalik A. Massive peptide sharing between viral and human proteomes. Peptides 2008; 29 (10) 1755-1766
  • 6 Trost B, Lucchese G, Stufano A, Bickis M, Kusalik A, Kanduc D. No human protein is exempt from bacterial motifs, not even one. Self Nonself 2010; 1 (04) 328-334
  • 7 Kanduc D. Peptide cross-reactivity: the original sin of vaccines. Front Biosci (Schol Ed) 2012; 4 (04) 1393-1401
  • 8 Kanduc D. From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry. Antibodies (Basel) 2020; 9 (03) 33
  • 9 Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, Jl Macario A, Cappello F. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev 2020; 19 (08) 102591
  • 10 Kanduc D. From anti-severe acute respiratory syndrome coronavirus 2 immune response to cancer onset via molecular mimicry and cross-reactivity. Glob Med Genet 2021; 8 (04) 176-182
  • 11 Kanduc D. Thromboses and hemostasis disorders associated with COVID-19: the possible causal role of cross-reactivity and immunological imprinting. Glob Med Genet 2021; 8 (04) 162-170
  • 12 Lucchese G. Cerebrospinal fluid findings in COVID-19 indicate autoimmunity. Lancet Microbe 2020; 1 (06) e242
  • 13 Landsteiner K, van der Scheer J. On the serological specificity of peptides. III. J Exp Med 1939; 69 (05) 705-719
  • 14 Reddehase MJ, Rothbard JB, Koszinowski UH. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 1989; 337 (6208): 651-653
  • 15 Endo M, Nunomura W, Takakuwa Y, Hatakeyama M, Higashi T. A novel epitope (pentapeptide) in the human hemoglobin beta chain. Hemoglobin 1998; 22 (04) 321-331
  • 16 Tiwari R, Geliebter J, Lucchese A, Mittelman A, Kanduc D. Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity. Peptides 2004; 25 (11) 1865-1871
  • 17 Pieczenik G. Are the universes of antibodies and antigens symmetrical?. Reprod Biomed Online 2003; 6 (02) 154-156
  • 18 Zeng W, Pagnon J, Jackson DC. The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. Mol Immunol 2007; 44 (15) 3724-3731
  • 19 Lucchese G, Stufano A, Trost B, Kusalik A, Kanduc D. Peptidology: short amino acid modules in cell biology and immunology. Amino Acids 2007; 33 (04) 703-707
  • 20 Kanduc D. Homology, similarity, and identity in peptide epitope immunodefinition. J Pept Sci 2012; 18 (08) 487-494
  • 21 Wu CH, Yeh LS, Huang H. et al. The protein information resource. Nucleic Acids Res 2003; 31 (01) 345-347
  • 22 Altschul SF, Madden TL, Schäffer AA. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25 (17) 3389-3402
  • 23 Boratyn GM, Thierry-Mieg J, Thierry-Mieg D, Busby B, Madden TL. Magic-BLAST, an accurate RNA-seq aligner for long and short reads. BMC Bioinformatics 2019; 20 (01) 405
  • 24 Bell PJ. The viral eukaryogenesis hypothesis: a key role for viruses in the emergence of eukaryotes from a prokaryotic world environment. Ann N Y Acad Sci 2009; 1178: 91-105
  • 25 Koonin EV, Senkevich TG, Dolja VV. The ancient Virus World and evolution of cells. Biol Direct 2006; 1: 29
  • 26 Kanduc D. The comparative biochemistry of viruses and humans: an evolutionary path towards autoimmunity. Biol Chem 2019; 400 (05) 629-638
  • 27 Kanduc D, Lucchese A, Mittelman A. Non-redundant peptidomes from DAPs: towards “the vaccine”?. Autoimmun Rev 2007; 6 (05) 290-294
  • 28 Kanduc D, Serpico R, Lucchese A, Shoenfeld Y. Correlating low-similarity peptide sequences and HIV B-cell epitopes. Autoimmun Rev 2008; 7 (04) 291-296
  • 29 Lucchese A, Serpico R, Crincoli V, Shoenfeld Y, Kanduc D. Sequence uniqueness as a molecular signature of HIV-1-derived B-cell epitopes. Int J Immunopathol Pharmacol 2009; 22 (03) 639-646
  • 30 Lucchese A, Guida A, Capone G, Petruzzi M, Lauritano D, Serpico R. Designing a peptide-based vaccine against Porphyromonas gingivalis. Front Biosci (Schol Ed) 2013; 5 (02) 631-637
  • 31 Kanduc D. Hydrophobicity and the physico-chemical basis of immunotolerance. Pathobiology 2020; 87 (04) 268-276
  • 32 Kanduc D. The role of proteomics in defining autoimmunity. Expert Rev Proteomics 2021; 18 (03) 177-184
  • 33 Patriquin G, Davidson RJ, Hatchette TF. et al. Generation of false-positive SARS-CoV-2 antigen results with testing conditions outside manufacturer recommendations: a scientific approach to pandemic misinformation. Microbiol Spectr 2021; 9 (02) e0068321
  • 34 Benoit J, Benoit SW, Lippi G, Henry BM. False negative RT-PCR or false positive serological testing in SARS-CoV-2 diagnostics? Navigating between Scylla and Charybdis to prevent misclassification bias in COVID-19 clinical investigations. Diagnosis (Berl) 2020; 7 (04) 405-407
  • 35 Verna R, Alallon W, Murakami M. et al. Analytical performance of COVID-19 detection methods (RT-PCR): scientific and societal concerns. Life (Basel) 2021; 11 (07) 660
  • 36 Corman VM, Landt O, Kaiser M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25 (03) 2000045
  • 37 Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir Med 2020; 8 (12) 1167-1168
  • 38 Braunstein GD, Schwartz L, Hymel P, Fielding J. False positive results with SARS-CoV-2 RT-PCR tests and how to evaluate a RT-PCR-positive test for the possibility of a false positive result. J Occup Environ Med 2021; 63 (03) e159-e162
  • 39 Viswanathan M, Kahwati L, Jahn B. et al. Universal screening for SARS-CoV-2 infection: a rapid review. Cochrane Database Syst Rev 2020; 9: CD013718
  • 40 Gubbay JB, Rilkoff H, Kristjanson HL. et al. Impact of COVID-19 pre-test probability on positive predictive value of high cycle threshold SARS-CoV-2 real-time reverse transcription PCR test results. Infect Control Hosp Epidemiol 2021; 1: 18
  • 41 Kanduc D. Nucleotide sequence sharing between the human genome and primers for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. Glob Med Genet 2022; 9 (02) 182-188
  • 42 Kanduc D. From Anti-SARS-CoV-2 immune response to the cytokine storm via molecular mimicry. Antibodies (Basel) 2021; 10 (04) 36
  • 43 Churilov LP, Kanduc D, Ryabkova VA. COVID-19: adrenal response and molecular mimicry. Isr Med Assoc J 2021; 23 (10) 618-619
  • 44 Kanduc D. SARS-CoV-2-induced immunosuppression: a molecular mimicry syndrome. Glob Med Genet 2022
  • 45 Khavinson V, Terekhov A, Kormilets D, Maryanovich A. Homology between SARS CoV-2 and human proteins. Sci Rep 2021; 11 (01) 17199

Address for correspondence

Darja Kanduc, PhD
Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari
Bari 70125
Italy   

Publication History

Article published online:
26 July 2022

© 2022. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Janeway Jr CA. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992; 13 (01) 11-16
  • 2 Rose NR. Negative selection, epitope mimicry and autoimmunity. Curr Opin Immunol 2017; 49: 51-55
  • 3 Kanduc D. Immunobiology: on the inexistence of a negative selection process. Adv Stud Biol 2020; 12 (01) 19-28
  • 4 Pradeu T, Carosella ED. On the definition of a criterion of immunogenicity. Proc Natl Acad Sci U S A 2006; 103 (47) 17858-17861
  • 5 Kanduc D, Stufano A, Lucchese G, Kusalik A. Massive peptide sharing between viral and human proteomes. Peptides 2008; 29 (10) 1755-1766
  • 6 Trost B, Lucchese G, Stufano A, Bickis M, Kusalik A, Kanduc D. No human protein is exempt from bacterial motifs, not even one. Self Nonself 2010; 1 (04) 328-334
  • 7 Kanduc D. Peptide cross-reactivity: the original sin of vaccines. Front Biosci (Schol Ed) 2012; 4 (04) 1393-1401
  • 8 Kanduc D. From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry. Antibodies (Basel) 2020; 9 (03) 33
  • 9 Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, Jl Macario A, Cappello F. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev 2020; 19 (08) 102591
  • 10 Kanduc D. From anti-severe acute respiratory syndrome coronavirus 2 immune response to cancer onset via molecular mimicry and cross-reactivity. Glob Med Genet 2021; 8 (04) 176-182
  • 11 Kanduc D. Thromboses and hemostasis disorders associated with COVID-19: the possible causal role of cross-reactivity and immunological imprinting. Glob Med Genet 2021; 8 (04) 162-170
  • 12 Lucchese G. Cerebrospinal fluid findings in COVID-19 indicate autoimmunity. Lancet Microbe 2020; 1 (06) e242
  • 13 Landsteiner K, van der Scheer J. On the serological specificity of peptides. III. J Exp Med 1939; 69 (05) 705-719
  • 14 Reddehase MJ, Rothbard JB, Koszinowski UH. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 1989; 337 (6208): 651-653
  • 15 Endo M, Nunomura W, Takakuwa Y, Hatakeyama M, Higashi T. A novel epitope (pentapeptide) in the human hemoglobin beta chain. Hemoglobin 1998; 22 (04) 321-331
  • 16 Tiwari R, Geliebter J, Lucchese A, Mittelman A, Kanduc D. Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity. Peptides 2004; 25 (11) 1865-1871
  • 17 Pieczenik G. Are the universes of antibodies and antigens symmetrical?. Reprod Biomed Online 2003; 6 (02) 154-156
  • 18 Zeng W, Pagnon J, Jackson DC. The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. Mol Immunol 2007; 44 (15) 3724-3731
  • 19 Lucchese G, Stufano A, Trost B, Kusalik A, Kanduc D. Peptidology: short amino acid modules in cell biology and immunology. Amino Acids 2007; 33 (04) 703-707
  • 20 Kanduc D. Homology, similarity, and identity in peptide epitope immunodefinition. J Pept Sci 2012; 18 (08) 487-494
  • 21 Wu CH, Yeh LS, Huang H. et al. The protein information resource. Nucleic Acids Res 2003; 31 (01) 345-347
  • 22 Altschul SF, Madden TL, Schäffer AA. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25 (17) 3389-3402
  • 23 Boratyn GM, Thierry-Mieg J, Thierry-Mieg D, Busby B, Madden TL. Magic-BLAST, an accurate RNA-seq aligner for long and short reads. BMC Bioinformatics 2019; 20 (01) 405
  • 24 Bell PJ. The viral eukaryogenesis hypothesis: a key role for viruses in the emergence of eukaryotes from a prokaryotic world environment. Ann N Y Acad Sci 2009; 1178: 91-105
  • 25 Koonin EV, Senkevich TG, Dolja VV. The ancient Virus World and evolution of cells. Biol Direct 2006; 1: 29
  • 26 Kanduc D. The comparative biochemistry of viruses and humans: an evolutionary path towards autoimmunity. Biol Chem 2019; 400 (05) 629-638
  • 27 Kanduc D, Lucchese A, Mittelman A. Non-redundant peptidomes from DAPs: towards “the vaccine”?. Autoimmun Rev 2007; 6 (05) 290-294
  • 28 Kanduc D, Serpico R, Lucchese A, Shoenfeld Y. Correlating low-similarity peptide sequences and HIV B-cell epitopes. Autoimmun Rev 2008; 7 (04) 291-296
  • 29 Lucchese A, Serpico R, Crincoli V, Shoenfeld Y, Kanduc D. Sequence uniqueness as a molecular signature of HIV-1-derived B-cell epitopes. Int J Immunopathol Pharmacol 2009; 22 (03) 639-646
  • 30 Lucchese A, Guida A, Capone G, Petruzzi M, Lauritano D, Serpico R. Designing a peptide-based vaccine against Porphyromonas gingivalis. Front Biosci (Schol Ed) 2013; 5 (02) 631-637
  • 31 Kanduc D. Hydrophobicity and the physico-chemical basis of immunotolerance. Pathobiology 2020; 87 (04) 268-276
  • 32 Kanduc D. The role of proteomics in defining autoimmunity. Expert Rev Proteomics 2021; 18 (03) 177-184
  • 33 Patriquin G, Davidson RJ, Hatchette TF. et al. Generation of false-positive SARS-CoV-2 antigen results with testing conditions outside manufacturer recommendations: a scientific approach to pandemic misinformation. Microbiol Spectr 2021; 9 (02) e0068321
  • 34 Benoit J, Benoit SW, Lippi G, Henry BM. False negative RT-PCR or false positive serological testing in SARS-CoV-2 diagnostics? Navigating between Scylla and Charybdis to prevent misclassification bias in COVID-19 clinical investigations. Diagnosis (Berl) 2020; 7 (04) 405-407
  • 35 Verna R, Alallon W, Murakami M. et al. Analytical performance of COVID-19 detection methods (RT-PCR): scientific and societal concerns. Life (Basel) 2021; 11 (07) 660
  • 36 Corman VM, Landt O, Kaiser M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25 (03) 2000045
  • 37 Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir Med 2020; 8 (12) 1167-1168
  • 38 Braunstein GD, Schwartz L, Hymel P, Fielding J. False positive results with SARS-CoV-2 RT-PCR tests and how to evaluate a RT-PCR-positive test for the possibility of a false positive result. J Occup Environ Med 2021; 63 (03) e159-e162
  • 39 Viswanathan M, Kahwati L, Jahn B. et al. Universal screening for SARS-CoV-2 infection: a rapid review. Cochrane Database Syst Rev 2020; 9: CD013718
  • 40 Gubbay JB, Rilkoff H, Kristjanson HL. et al. Impact of COVID-19 pre-test probability on positive predictive value of high cycle threshold SARS-CoV-2 real-time reverse transcription PCR test results. Infect Control Hosp Epidemiol 2021; 1: 18
  • 41 Kanduc D. Nucleotide sequence sharing between the human genome and primers for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. Glob Med Genet 2022; 9 (02) 182-188
  • 42 Kanduc D. From Anti-SARS-CoV-2 immune response to the cytokine storm via molecular mimicry. Antibodies (Basel) 2021; 10 (04) 36
  • 43 Churilov LP, Kanduc D, Ryabkova VA. COVID-19: adrenal response and molecular mimicry. Isr Med Assoc J 2021; 23 (10) 618-619
  • 44 Kanduc D. SARS-CoV-2-induced immunosuppression: a molecular mimicry syndrome. Glob Med Genet 2022
  • 45 Khavinson V, Terekhov A, Kormilets D, Maryanovich A. Homology between SARS CoV-2 and human proteins. Sci Rep 2021; 11 (01) 17199